Microbial Monitoring For Biological Drug Substance Manufacturing: An Industry Perspective

References

1. 1.
   Quality Guideline Q6B: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products; International Conference on Harmonisation: 1999. www.ich.org (accessed June 24, 2014).
2. 2.
   Quality Guideline Q7A: Good Manufacturing Practice for Active Pharmaceutical Ingredients; International Conference on Harmonisation: 2005. www.ich.org (accessed June 24, 2014).
3. 3.
   Technical Report No. 33: Evaluation, Validation, and Implementation of Alternative and Rapid Microbiological Methods; Parenteral Drug Association: 2013. www.pda.org (accessed June 24, 2014).
4. 4.
   General Chapter <1111> Microbial Examination of Nonsterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use. In USP 37/NF32; U.S. Pharmacopeia: 2014. www.usp.org
5. 5.
   Annex 1. Manufacture of Sterile Medicinal Products; EudraLex, The Rules Governing Medicinal Products in the European Union, Volume 4; EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use. Brussels, 25 November 2008. www.ec.europa.eu
6. 6.
   Annex 2. Manufacture of Biological active substances and Medicinal Products for Human Use; EudraLex, The Rules Governing Medicinal Products in the European Union, Volume 4; EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use. Brussels, 25 November 2008. www.ec.europa.eu
7. 7.
   1. von Wintzingerode F.

   Biologics Drug Substance Production: Safety aspects of bioburden contaminations of non-sterile process intermediates. ECA, European Microbiology Conference, Copenhagen, April 24–25, 2013.